TPMG Clinical Research Division in Newport News is recruiting patients for a clinical research trial to explore the potential treatment for COVID-19 in recently diagnosed patients who are at risk for worsening symptoms.
This investigational treatment trial is the first in a trio of interlocking trials that target the virus itself in order to minimize hospitalizations and deaths and possibly minimize worsening symptoms of COVID-19.
As of yet, there are no oral outpatient treatments for COVID-19. Many drugs target specific symptoms such as nausea and headaches, whereas this current treatment looks to suppress the virus itself rather than treat its symptoms. The first trial will focus on unvaccinated patients with an increased risk of hospitalizations, including those with high blood pressure, diabetes, asthma and other chronic conditions. Patients must have a COVID-19 diagnosis within the last five days and be symptomatic to qualify.
“This trial is going to be most beneficial f...
To view the rest of this article, you must log in. If you do not have an account with us, please subscribe here.